Treatment of pulmonary hypertension in patients with connective tissue disease and interstitial lung disease.

PubWeight™: 0.78‹?›

🔗 View Article (PMC 3006151)

Published in Can Respir J on December 17, 2010

Authors

Shikha Mittoo1, Thomas Jacob, Andrea Craig, Zoheir Bshouty

Author Affiliations

1: Department of Medicine, University of Manitoba, Winnipeg, Manitoba. smittoo@mtsinai.on.ca

Articles cited by this

Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society. Am Rev Respir Dis (1991) 13.67

Bosentan therapy for pulmonary arterial hypertension. N Engl J Med (2002) 11.18

Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med (1998) 6.10

Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis (2007) 4.88

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med (2000) 4.07

Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med (2008) 3.67

Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis (2003) 2.85

Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis (2006) 2.28

Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum (1994) 2.11

The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum (2005) 1.91

Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis (2007) 1.72

Primary pulmonary hypertension in a patient with systemic lupus erythematosus: partial improvement with cyclophosphamide. J Rheumatol (1993) 1.71

Reference values of pulmonary function tests for Canadian Caucasians. Can Respir J (2004) 1.58

Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum (2008) 1.40

Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum (2009) 1.40

Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis (2007) 1.27

Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum (2006) 1.21

Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med (1999) 1.13

Pulmonary function in progressive systemic sclerosis. Comparison of CREST syndrome variant with diffuse scleroderma. Chest (1983) 1.03

Precapillary pulmonary hypertension dramatically improved with high doses of corticosteroids during systemic lupus erythematosus. J Rheumatol (1994) 0.90

Review: antiphospholipid antibodies and the lung. J Rheumatol (1995) 0.86

Successful treatment with immunosuppression, anticoagulation and vasodilator therapy of pulmonary hypertension in SLE associated with secondary antiphospholipid syndrome. Lupus (1998) 0.84

Remission of precapillary pulmonary hypertension in systemic lupus erythematosus. J R Soc Med (2001) 0.78

[Nightly home artificial respiration in juvenile Pompe's disease with pulmonary hypertension and right cardiac insufficiency]. Dtsch Med Wochenschr (1989) 0.77

Lupus-associated pulmonary hypertension: long-term response to vasoactive therapy. Respir Med (2007) 0.77

Articles by these authors

Diagnosis of intra-amniotic infection by proteomic profiling and identification of novel biomarkers. JAMA (2004) 2.53

Identification of novel protein biomarkers of preterm birth in human cervical-vaginal fluid. J Proteome Res (2007) 1.58

Comprehensive proteomic analysis of human cervical-vaginal fluid. J Proteome Res (2007) 1.46

Proteomic analysis of cervical-vaginal fluid: identification of novel biomarkers for detection of intra-amniotic infection. J Proteome Res (2007) 1.23

Comprehensive proteomic analysis of the human amniotic fluid proteome: gestational age-dependent changes. J Proteome Res (2007) 1.23

Proteomic analysis of maternal serum in down syndrome: identification of novel protein biomarkers. J Proteome Res (2007) 1.06

Noninvasive diagnosis of intraamniotic infection: proteomic biomarkers in vaginal fluid. Am J Obstet Gynecol (2010) 0.96

Comprehensive maternal serum proteomic profiles of preclinical and clinical preeclampsia. J Proteome Res (2010) 0.91

Effect of maintenance azithromycin on established bronchiolitis obliterans syndrome in lung transplant patients. Can Respir J (2008) 0.84

Basic principles of control of breathing. Respir Care Clin N Am (2005) 0.79

Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy. Can Respir J (2008) 0.76

Comparison of per cent predicted and percentile values for pulmonary function test interpretation. Can Respir J (2009) 0.75

An atypical presentation of liver enzyme elevation resulting from bosentan use. Can Respir J (2009) 0.75

Vascular compromise and hemodynamics in pulmonary arterial hypertension: model predictions. Can Respir J (2012) 0.75

Cultural diversity. Nursing (2014) 0.75

Directing therapy in pulmonary arterial hypertension using a target 6 min walk distance. Can Respir J (2013) 0.75

Ventilator advisory system employing load and tolerance strategy recommends appropriate pressure support ventilation settings: multisite validation study. Chest (2008) 0.75

A rare case of segmental testicular infarction. Urology (2007) 0.75